Chronos Archive seal
The Human Record

Madam C. J. Walker

Case HR-ET019 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
December 23, 1867 – May 25, 1919
Synthetic DOB
1976-12-23
Index visit
2026-02-09 at age 49
Synthetic MRN
HR-ET019-SYN

Teaching objective: Hypertension with chronic kidney disease in a 49-year-old Black woman who founded and runs a national hair-care company and travels most weeks to train her sales agents. The episode covers accurate office measurement and 24-hour ambulatory and home monitoring under the 2025 AHA/ACC guideline; kidney function by the race-free CKD-EPI 2021 equation, stated explicitly, with the urine albumin-to-creatinine ratio, chronicity and KDIGO 2024 staging and risk; an angiotensin receptor blocker titrated to the maximum dose, an SGLT2 inhibitor for CKD with albuminuria, and a calcium channel blocker to reach goal; a statin chosen by shared decision; potassium and creatinine after each start or increase; sick-day rules tested by a real gastroenteritis; sodium counseling built on the food she likes; nephrology consultation; and a work and rest plan she sets herself. The teaching contrast is the historical advice to rest and slow down: here the risks are stated plainly, the treatment does the work, and she decides how she lives. Race and medicine: the eGFR uses no race term, the first medicine is chosen for the albuminuria rather than for her race, and APOL1 genetic testing is offered with counseling and left to her choice.

Historical timeline

DateEventClaims
December 23, 1867Born Sarah Breedlove in Delta, Louisiana, to formerly enslaved parents.CLM-0001
by 1875Both parents had died by the time she was seven.CLM-0002
1904Hair loss and scalp disease; began selling hair-care products as an agent.CLM-0003
January 4, 1906Married Charles Joseph Walker in Denver and began her own company as Madam C. J. Walker.CLM-0004
1910Company moved to Indianapolis; thousands of agents trained.CLM-0004, CLM-0005
1916Rest cure at Hot Springs, Arkansas, for her health; high blood pressure.CLM-0006
July 1917Joined the committee of the Negro Silent Protest Parade petitioning for a federal law against lynching.CLM-0010
mid-November 1917Nephritis worsened by hypertension diagnosed; rest at Battle Creek advised.CLM-0007
April 1919Gravely ill in St. Louis; returned to New York.CLM-0008
May 25, 1919Died at Villa Lewaro, Irvington-on-Hudson, at 51.CLM-0009

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Madam C. J. Walker was born Sarah Breedlove on December 23, 1867, in Delta, Louisiana, the daughter of Owen and Minerva Anderson Breedlove. Both parents had been enslaved on a Madison Parish plantation, and she was their first child born into freedom. confirmed Madam C.J. Walker (Famous Hoosiers) supports
Jeansonne G, Luhrssen D. Madam C. J. Walker supports
McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives supports
Madam C.J. Walker (biography) supports
Bundles A. The Centennial of Madam C. J. Walker's Death, May 25, 1919 supports
HISTMED Master Roster v3 context
D Both her parents had died by the time she was seven, and she went to live with an older sister and moved across the river to Vicksburg, Mississippi. She married Moses McWilliams at fourteen, had her only child, Lelia (later A'Lelia), and was widowed at twenty. She then moved to St. Louis, where she worked as a laundress and cook, sometimes for as little as a dollar a day.
Anchors her early loss of both parents (cause not recorded) and the years of heavy physical work in the modern social history.
confirmed Jeansonne G, Luhrssen D. Madam C. J. Walker supports
McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives supports
Madam C.J. Walker (biography) supports
D While working as a laundress she began to lose her hair, a problem many Black women of her time shared. Her biographers attribute it to scalp disease such as dandruff, poor diet, a hard life and harsh washing products, in an era when most homes lacked indoor plumbing. In 1904 she began using and selling another Black woman's hair grower as a sales agent, then developed her own sulfur-containing ointments and shampoos to treat scalp disease.
History only; the origin of her products. The modern episode adds no scalp or hair diagnosis.
confirmed Madam C.J. Walker (Famous Hoosiers) supports
Jeansonne G, Luhrssen D. Madam C. J. Walker supports
Madam C.J. Walker (biography) supports
Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
D In Denver she married Charles Joseph Walker, a newspaper advertising salesman (in January 1906, or 1905 in one account), and began calling herself Madam Walker, in part to avoid the familiar forms of address then used for Black women. She launched her own hair-care line there, set up headquarters and a training school for her agents in Pittsburgh in 1908, and moved the company to Indianapolis in 1910. She trained thousands of sales agents, "hair culturists," who earned a share of the profits. She kept the name after the marriage ended.
Anchors her chosen form of address and her work as a founder who trained agents and traveled constantly to sell and teach.
confirmed Jeansonne G, Luhrssen D. Madam C. J. Walker supports
McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives supports
Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
Madam C.J. Walker (Famous Hoosiers) supports
Madam Walker supports
D As her wealth grew she became a philanthropist and activist: she gave to the YWCA and paid tuition for students at Tuskegee Institute, and in 1915 she sued over discrimination at an Indianapolis theater.
Anchors her philanthropy and civic work in the modern social history.
confirmed Madam C.J. Walker (biography) supports
McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives supports
Madam C.J. Walker (Famous Hoosiers) supports
D In 1917 she joined the committee of the Negro Silent Protest Parade in petitioning the President and Congress to make lynching a national crime. She gave $5,000 to the NAACP's anti-lynching work, and by her own report her company had more than twenty thousand agents by 1919.
History after the index date; anchors the later civic work and the size of her agent network.
confirmed McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives supports
Madam C.J. Walker (biography) supports
Jeansonne G, Luhrssen D. Madam C. J. Walker supports
D The physical demands she placed on herself undermined her health, and she suffered from high blood pressure. She went for a rest cure at Hot Springs, Arkansas, in 1916, but otherwise did not slow her pace.
The anchor for the modern hypertension. The teaching contrast: the historical advice was to rest and slow down; the modern plan treats the blood pressure and fits care around the work she chooses.
confirmed Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
Madam C.J. Walker (Famous Hoosiers) supports
D By mid-November 1917 a Chicago physician, Dr. George Sauer, diagnosed nephritis, an often irreversible inflammation of the kidneys made worse by her worsening hypertension, and advised an indefinite stay at the Battle Creek Sanitarium in Michigan, where she took a rest cure that year.
History after the modern episode. Anchors the modern kidney disease; the modern kidney findings are synthetic.
confirmed Bundles A. On Her Own Ground: The Life and Times of Madam C. J. Walker (Scribner, 2001), chapter 17, as quoted in the Wikipedia article on her supports
Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
D She moved into Villa Lewaro, her house at Irvington-on-Hudson, New York (in 1918; 1917 in one account). In April 1919 she became gravely ill in St. Louis and returned to New York.
History after the modern episode.
confirmed Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
Madam C.J. Walker (Famous Hoosiers) supports
Jeansonne G, Luhrssen D. Madam C. J. Walker supports
D She died on May 25, 1919, at Villa Lewaro, at 51. Accounts of the cause differ: chronic interstitial nephritis; kidney failure; or high blood pressure and kidney failure.
History only, two years after the modern episode. Anchors the hypertension and kidney disease.
confirmed Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia supports
Madam C.J. Walker (biography) supports
Madam Walker supports
Madam C.J. Walker (Famous Hoosiers) supports
Jeansonne G, Luhrssen D. Madam C. J. Walker supports
Bundles A. The Centennial of Madam C. J. Walker's Death, May 25, 1919 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm resolved confirmed active CLM-0006
S Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated resolved confirmed active CLM-0007
S Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure active confirmed both_with_link CLM-0006, CLM-0007
S Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% active confirmed active CLM-0007, CLM-0009
S Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) active confirmed active
S Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolved resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-09 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-02-09 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-02-09 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-02-09 Creatinine [Mass/volume] in Serum or Plasma 1.22 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-02-09 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 54 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-02-09 Albumin/Creatinine [Mass Ratio] in Urine 286 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 2026-02-09 Hemoglobin A1c/Hemoglobin.total in Blood 5.4%
Reference Below 5.7% is normal
http://loinc.org · 4548-4
S 2026-02-09 Cholesterol [Mass/volume] in Serum or Plasma 250 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-02-09 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 174 mg/dL (high)
Reference Below 130 mg/dL; lower on treatment by at least 30%
http://loinc.org · 13457-7
S 2026-02-09 Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 mg/dL (low)
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-02-09 Triglyceride [Mass/volume] in Serum or Plasma 150 mg/dL (high)
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-02-09 Hemoglobin [Mass/volume] in Blood 12.4 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-02-09 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-02-09 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-02-23 Albumin/Creatinine [Mass Ratio] in Urine 294 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 2026-02-23 Creatinine [Mass/volume] in Serum or Plasma 1.21 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-02-23 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-02-23 Calcium [Mass/volume] in Serum or Plasma 9.4 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-02-23 Phosphate [Mass/volume] in Serum or Plasma 3.6 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 2026-02-23 Parathyrin.intact [Mass/volume] in Serum or Plasma 58 pg/mL
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 2026-02-23 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-03-09 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-09 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-09 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-09 Creatinine [Mass/volume] in Serum or Plasma 1.29 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-03-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 51 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-04-13 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-04-13 Potassium [Moles/volume] in Serum or Plasma 4.9 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-04-13 Carbon dioxide, total [Moles/volume] in Serum or Plasma 21 mmol/L (low)
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-04-13 Creatinine [Mass/volume] in Serum or Plasma 1.46 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-04-13 Glucose [Mass/volume] in Serum or Plasma 88 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-04-13 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 44 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-04-27 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-04-27 Potassium [Moles/volume] in Serum or Plasma 4.7 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-04-27 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-04-27 Creatinine [Mass/volume] in Serum or Plasma 1.31 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-04-27 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 50 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-04-27 Albumin/Creatinine [Mass Ratio] in Urine 176 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 2026-04-27 Cholesterol [Mass/volume] in Serum or Plasma 172 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-04-27 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 mg/dL
Reference Below 130 mg/dL; lower on treatment by at least 30%
http://loinc.org · 13457-7
S 2026-04-27 Cholesterol in HDL [Mass/volume] in Serum or Plasma 48 mg/dL (low)
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-04-27 Triglyceride [Mass/volume] in Serum or Plasma 130 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-04-27 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-08-17 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-08-17 Potassium [Moles/volume] in Serum or Plasma 4.8 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-08-17 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-08-17 Creatinine [Mass/volume] in Serum or Plasma 1.3 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-08-17 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 50 mL/min/1.73 m² (low)
Reference 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a
http://loinc.org · 98979-8
S 2026-08-17 Albumin/Creatinine [Mass Ratio] in Urine 128 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 2026-08-17 Hemoglobin [Mass/volume] in Blood 12.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-08-17 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-06-08 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-06-08 Total score [AUDIT-C] 1 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-09Body height163 cm8302-2S
2026-02-09Body weight79 kg29463-7S
2026-02-09Body mass index (BMI) [Ratio]29.7 kg/m239156-5S
2026-02-09Systolic blood pressure166 mm[Hg]8480-6S
2026-02-09Diastolic blood pressure102 mm[Hg]8462-4S
2026-02-09Heart rate82 /min8867-4S
2026-02-09Respiratory rate16 /min9279-1S
2026-02-09Body temperature36.7 Cel8310-5S
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-02-23Body height163 cm8302-2S
2026-02-23Body weight78.6 kg29463-7S
2026-02-23Body mass index (BMI) [Ratio]29.6 kg/m239156-5S
2026-02-23Systolic blood pressure160 mm[Hg]8480-6S
2026-02-23Diastolic blood pressure100 mm[Hg]8462-4S
2026-02-23Heart rate80 /min8867-4S
2026-02-23Respiratory rate16 /min9279-1S
2026-02-23Body temperature36.6 Cel8310-5S
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-03-09Body height163 cm8302-2S
2026-03-09Body weight78.2 kg29463-7S
2026-03-09Body mass index (BMI) [Ratio]29.4 kg/m239156-5S
2026-03-09Systolic blood pressure148 mm[Hg]8480-6S
2026-03-09Diastolic blood pressure92 mm[Hg]8462-4S
2026-03-09Heart rate78 /min8867-4S
2026-03-09Respiratory rate16 /min9279-1S
2026-03-09Body temperature36.7 Cel8310-5S
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-04-27Body height163 cm8302-2S
2026-04-27Body weight77.2 kg29463-7S
2026-04-27Body mass index (BMI) [Ratio]29.1 kg/m239156-5S
2026-04-27Systolic blood pressure136 mm[Hg]8480-6S
2026-04-27Diastolic blood pressure86 mm[Hg]8462-4S
2026-04-27Heart rate76 /min8867-4S
2026-04-27Respiratory rate16 /min9279-1S
2026-04-27Body temperature36.6 Cel8310-5S
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-17Body height163 cm8302-2S
2026-08-17Body weight75.8 kg29463-7S
2026-08-17Body mass index (BMI) [Ratio]28.5 kg/m239156-5S
2026-08-17Systolic blood pressure122 mm[Hg]8480-6S
2026-08-17Diastolic blood pressure76 mm[Hg]8462-4S
2026-08-17Heart rate72 /min8867-4S
2026-08-17Respiratory rate16 /min9279-1S
2026-08-17Body temperature36.7 Cel8310-5S
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-04-13Body height163 cm8302-2S
2026-04-13Body weight76.4 kg29463-7S
2026-04-13Body mass index (BMI) [Ratio]28.8 kg/m239156-5S
2026-04-13Systolic blood pressure112 mm[Hg]8480-6S
2026-04-13Diastolic blood pressure72 mm[Hg]8462-4S
2026-04-13Heart rate96 /min8867-4S
2026-04-13Respiratory rate16 /min9279-1S
2026-04-13Body temperature37.4 Cel8310-5S
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-06-08Body height163 cm8302-2S
2026-06-08Body weight76.6 kg29463-7S
2026-06-08Body mass index (BMI) [Ratio]28.8 kg/m239156-5S
2026-06-08Systolic blood pressure126 mm[Hg]8480-6S
2026-06-08Diastolic blood pressure80 mm[Hg]8462-4S
2026-06-08Heart rate74 /min8867-4S
2026-06-08Respiratory rate16 /min9279-1S
2026-06-08Body temperature36.7 Cel8310-5S
2026-06-08Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated2026-08-17completed122/76 in the clinic; home average 123/77 on losartan 100 mg and amlodipine 5 mg
Urine albumin-to-creatinine ratio lower by at least 30% within six months2026-08-17completed286 to 294 mg/g at baseline; 128 mg/g at six months, 56% lower
Kidney function stable, without a fall in eGFR of more than 30% after starting treatment2026-08-17completedeGFR 54 to 55 at baseline; 50 to 51 on treatment, a dip of under 10%
Sodium under 2 g a day using foods she likes, at home and on the road2026-08-17activeSalt-free seasoning at home and ordering strategies on the road; restaurant meals still the hardest part
LDL cholesterol lower by at least 30%2026-04-27completed174 to 98 mg/dL on atorvastatin 20 mg, 44% lower
Care that fits her work: every check scheduled around her travel, by her choice2026-08-17completedLaboratory checks booked before trips are planned after two missed checks; video visits between trips

Interventions

InterventionStatusGuideline
Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travelcompletedGL-KDIGO-CKD-2024, GL-CMID-2026
Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weekscompletedGL-AHA-HTN-2025, GL-CMID-2026
Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxencompletedGL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021, GL-CMID-2026
Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort EquationscompletedGL-AHA-HTN-2025, GL-ACC-CHOL-2018, GL-CMID-2026
Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settledcompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024
Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at homecompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024
Mood and stress: PHQ-9 at intake and yearlycompletedGL-USPSTF-DEP-2023, GL-CMID-2026
Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumncompletedGL-CDC-IMZ-2026
Gastroenteritis: oral rehydration, ondansetron as needed, losartan and empagliflozin held until she has eaten and drunk normally for 24 hours, then restarted; a metabolic panel within a weekcompletedGL-KDIGO-CKD-2024
As the nephrologist advised: losartan 50 mg, increased to 100 mg at two weeks if potassium and creatinine allow; empagliflozin 10 mg daily; sick-day rules for both; potassium and creatinine two to four weeks after each start or increase, accepting a creatinine rise of up to 30%; urine albumin at about three months, then every six months; blood pressure goal below 130/80, lower toward a systolic of 120 if well tolerated, with amlodipine as the next medicinecompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026
Atorvastatin 20 mg daily, chosen with her after reviewing her 10-year ASCVD risk of 7.9% with CKD as a risk enhancer; lipid panel and ALT at four to twelve weekscompletedGL-ACC-CHOL-2018, GL-KDIGO-CKD-2024, GL-CMID-2026
Amlodipine 5 mg added for home readings above goal on losartan 100 mg; every laboratory check booked on a home day before her trips are scheduled, by her office, after two missed checkscompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Madam C.J. Walker (Famous Hoosiers) Indiana Historical Society biography
SRC-0002 Jeansonne G, Luhrssen D. Madam C. J. Walker 64 Parishes (Louisiana Endowment for the Humanities) biography
SRC-0003 McNatt M. Madam C. J. Walker's Rags to Riches Story Found in the Holdings of the National Archives U.S. National Archives (The Text Message blog) government
SRC-0004 Madam C.J. Walker (biography) National Women's History Museum biography
SRC-0005 Walker, Madame C.J. (1867-1919), Women in World History: A Biographical Encyclopedia Gale, via Encyclopedia.com biography
SRC-0006 Madam Walker Lemelson Center for the Study of Invention and Innovation biography
SRC-0007 Bundles A. On Her Own Ground: The Life and Times of Madam C. J. Walker (Scribner, 2001), chapter 17, as quoted in the Wikipedia article on her Wikipedia (quoting the Scribner biography) biography
SRC-0008 Bundles A. The Centennial of Madam C. J. Walker's Death, May 25, 1919 A'Lelia Bundles (author's site) biography
SRC-0009 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the confirmation of hypertension by ambulatory monitoring, the CKD G3a A2 staging with the race-free eGFR and prior results for chronicity, losartan titration and the creatinine and potassium checks, empagliflozin without diabetes, the statin chosen at intermediate risk, the sick-day handling during gastroenteritis, and the APOL1 discussion.
provenance reviewnot_startedSources: the Indiana Historical Society, 64 Parishes, the National Archives, the National Women's History Museum, the Gale Women in World History entry, the Lemelson Center, A'Lelia Bundles's site, and a passage of her biography quoted in Wikipedia. The NMAAHC pages, the New York Times obituary and the biography itself could not be read.
safe messaging reviewnot_startedNo mental health claim is made; the mood screen is synthetic and below the threshold for a safety assessment. Her history is told with attention to slavery, poverty and the forms of address she refused, without stereotype; her work is treated as hers to direct.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.